The number of specialty drugs and biologics making it to market slipped from 25 in 2012 to 13 last year. Cancer continues to be a hotbed of specialty drug development. Of the 13 specialty drugs and biologics approved last year, nine carry oncology indications and hefty price tags. None were chemotherapies.
